Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders treatment solutions, has announced its upcoming first quarter 2025 financial results release. The company will disclose its Q1 2025 financial and operating results before the market opens on Tuesday, May 6, 2025.
A conference call to discuss the results is scheduled for 8:30 a.m. Eastern Time on the same day. Interested parties can access the live broadcast in listen-only mode via webcast, with telephone participants encouraged to register and join 10 minutes before the event start.
Neuronetics (NASDAQ: STIM), un'azienda di tecnologia medica specializzata in soluzioni per il trattamento dei disturbi neuro-sanitari, ha annunciato la pubblicazione dei risultati finanziari del primo trimestre 2025. La società renderà noti i risultati finanziari e operativi del Q1 2025 prima dell'apertura dei mercati, martedì 6 maggio 2025.
Una conferenza telefonica per discutere i risultati è prevista per le 8:30 del mattino, ora orientale, lo stesso giorno. Gli interessati potranno seguire la diretta in modalità solo ascolto tramite webcast, mentre i partecipanti telefonici sono invitati a registrarsi e collegarsi 10 minuti prima dell'inizio dell'evento.
Neuronetics (NASDAQ: STIM), una empresa de tecnología médica especializada en soluciones para el tratamiento de trastornos neuro-sanitarios, ha anunciado la publicación de sus resultados financieros del primer trimestre de 2025. La compañía dará a conocer sus resultados financieros y operativos del Q1 2025 antes de la apertura del mercado el martes 6 de mayo de 2025.
Está programada una conferencia telefónica para discutir los resultados a las 8:30 a.m., hora del Este, el mismo día. Las personas interesadas podrán acceder a la transmisión en vivo en modo solo escucha a través de webcast, y se recomienda a los participantes telefónicos que se registren y se unan 10 minutos antes del inicio del evento.
Neuronetics (NASDAQ: STIM)는 신경 건강 장애 치료 솔루션을 전문으로 하는 의료 기술 회사로, 2025년 1분기 재무 결과 발표를 예고했습니다. 회사는 2025년 5월 6일 화요일 시장 개장 전 1분기 2025년 재무 및 운영 결과를 공개할 예정입니다.
결과를 논의하기 위한 컨퍼런스 콜은 같은 날 동부 표준시 기준 오전 8시 30분에 예정되어 있습니다. 관심 있는 분들은 웹캐스트를 통해 청취 전용 모드로 생중계에 접속할 수 있으며, 전화 참가자는 행사 시작 10분 전에 등록하고 참여할 것을 권장합니다.
Neuronetics (NASDAQ : STIM), une entreprise de technologie médicale spécialisée dans les solutions de traitement des troubles neuro-sanitaires, a annoncé la publication prochaine de ses résultats financiers du premier trimestre 2025. La société dévoilera ses résultats financiers et opérationnels du T1 2025 avant l'ouverture des marchés, le mardi 6 mai 2025.
Une conférence téléphonique pour discuter des résultats est prévue à 8h30, heure de l'Est, le même jour. Les personnes intéressées pourront accéder à la diffusion en direct en mode écoute seule via webcast, et les participants par téléphone sont invités à s'inscrire et à se connecter 10 minutes avant le début de l'événement.
Neuronetics (NASDAQ: STIM), ein Medizintechnikunternehmen, das sich auf Behandlungslösungen für neurogesundheitliche Störungen spezialisiert hat, hat die Veröffentlichung seiner Finanzergebnisse für das erste Quartal 2025 angekündigt. Das Unternehmen wird die finanziellen und operativen Ergebnisse des Q1 2025 vor Markteröffnung am Dienstag, den 6. Mai 2025, bekannt geben.
Eine Telefonkonferenz zur Besprechung der Ergebnisse ist für denselben Tag um 8:30 Uhr Eastern Time angesetzt. Interessierte können die Live-Übertragung im Nur-Hör-Modus per Webcast verfolgen, Telefonteilnehmer werden gebeten, sich 10 Minuten vor Beginn der Veranstaltung zu registrieren und einzuwählen.
- None.
- None.
MALVERN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2025 financial and operating results prior to market open on Tuesday, May 6, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/knieqjnc. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 7.1 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
When will Neuronetics (STIM) release Q1 2025 earnings?
How can investors join Neuronetics (STIM) Q1 2025 earnings call?
What time is Neuronetics (STIM) Q1 2025 earnings call?
Is Neuronetics (STIM) Q1 2025 earnings call available for replay?
